Wednesday, February 10, 2010, 11:24AM AEST - The Australian Stockmarket closes in 4 hours and 41 minutes.
To create a watchlist or portfolio of shares, Register

BioDelivery Sciences International Inc. (BDSI)

8:00AM AEST: 3.52 USD  Up 0.04 (1.15%)  
 MORE ON BDSI 
Quotes
HereSummary
Charts
Technical Analysis
News & Info
Company
Analyst Coverage
Ownership
Financials
 BioDelivery Sciences Internatio (NCM:BDSI) Delayed quote dataEdit
Last Trade:3.52 USD
Trade Time: 8:00AM AEST
Change:Up 0.04 (1.15%)
Prev Close:3.48
Open:3.57
Bid:3.25 x 200
Ask:4.01 x 5000
1y Target Est:7.75
Day's Range:3.50 - 3.56
52wk Range:2.42 - 8.29
Volume:24,688
Avg Vol (3m):93,233.9
Market Cap:73.98M
P/E (ttm):N/A
EPS (ttm):-1.51
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
 Add BDSI to Portfolio   Download Data

 HEADLINES 
BIODELIVERY SCIENCES INTERNATIONAL INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
EDGAR Online (Wed, Jan 13)
BDSI eyes $2B market with FDA meeting
at bizjournals.com (Wed, Jan 13)
BioDelivery Sciences Granted a Meeting with FDA to Discuss the Clinical Development of BEMA Granisetron
Business Wire (Tue, Jan 12)
Biotech Stock Mailbag: Novelos Therapeutics
at TheStreet.com (Fri, Jan 8)
BioDelivery Sciences to Present at the OneMedForum Emerging Company Finance Conference
Business Wire (Wed, Jan 6)
BIODELIVERY SCIENCES INTERNATIONAL INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Stat
EDGAR Online (Fri, Jan 1)
BioDelivery Sciences Set to Take Off in 2010
at Seeking Alpha (Sat, Dec 19)
BIODELIVERY SCIENCES INTERNATIONAL INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
EDGAR Online (Sat, Dec 19)
BDSI’s dental-pain film does well in phase II trials
at bizjournals.com (Fri, Dec 18)
Hovnanian, BioDelivery: Early Volume Plays
at TheStreet.com (Thu, Dec 17)
BioDelivery Sciences Announces Positive Phase 2 Pain Trial Results for BEMA Buprenorphine
Business Wire (Thu, Dec 17)
More Headlines for BDSI...

 ANALYST 
EPS Est (next year) (Dec-09) :1.55
EPS Est (in 2 years) (Dec-10) :-0.14
Avg Rec (current)*:1.3
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
BioDelivery Sciences International, Inc. operates as a specialty pharmaceutical company in the United States. Its patented drug delivery technologies include BEMA drug delivery technology and Bioral cochleate drug delivery technology.

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
Latest News7 Indices